[March 22, 2013]

Research and Markets: Epzicom (HIV) - Forecast and Market Analysis to 2022

Research and Markets (http://www.researchandmarkets.com/research/5hm6f8/epzicom_hiv) has announced the addition of the "Epzicom (HIV) - Forecast and Market Analysis to 2022" report to their offering.

Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence f single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.

ViiV's Epzicom is a fixed-dose combination of two NRTIs, Ziagen (abacavir sulfate/ABC) and Epivir (lamivudine/3TC). The drug is indicated in combination with other antiretrovirals for the treatment of HIV infection for adults, and for adults and adolescents over the age of 12 years, in the US and EU, respectively (Epzicom Summary of Prescribing Information, 2012; Kivexa Summary of Product Characteristics, 2012).

Scope

- Overview of HIV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Epzicom including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Epzicom for the top nine countries from 2012 to 2022.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for HIV

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of Epzicom performance

- Obtain sales forecast for Epzicom from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

For more information visit http://www.researchandmarkets.com/research/5hm6f8/epzicom_hiv

[ Back To Technology News's Homepage ]